These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 160192)

  • 21. Characterization of gamma-aminobutyric acid binding sites on crude synaptic membranes.
    Kurioka S; Hayata H; Matsuda M
    J Neurochem; 1981 Aug; 37(2):283-8. PubMed ID: 6267196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders.
    Ge J; Barnes NM
    Eur J Pharmacol; 1996 Feb; 297(3):299-306. PubMed ID: 8666063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotransmitter receptor localizations: brain lesion induced alterations in benzodiazepine, GABA, beta-adrenergic and histamine H1-receptor binding.
    Chang RS; Tran VT; Snyder SH
    Brain Res; 1980 May; 190(1):95-110. PubMed ID: 6103733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
    Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
    Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of principles of steady-state kinetics to the estimation of gamma-aminobutyric acid turnover rate in nuclei of rat brain.
    Bertilsson L; Mao CC; Costa E
    J Pharmacol Exp Ther; 1977 Feb; 200(2):277-84. PubMed ID: 839439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Huntington's chorea. Changes in neurotransmitter receptors in the brain.
    Enna SJ; Bird ED; Bennett JP; Bylund DB; Yamamura HI; Iversen LL; Snyder SH
    N Engl J Med; 1976 Jun; 294(24):1305-9. PubMed ID: 4733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurochemical and neuropharmacological indications for the involvement of GABA and glycine receptors in neuropsychiatric disorders.
    Lloyd KG; DeMontis G; Broekkamp CL; Thuret F; Worms P
    Adv Biochem Psychopharmacol; 1983; 37():137-48. PubMed ID: 6138947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models.
    Martínez-Mir MI; Pollard H; Moreau J; Traiffort E; Ruat M; Schwartz JC; Palacios JM
    Synapse; 1993 Nov; 15(3):209-20. PubMed ID: 7904088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phylogenetic distribution of bicuculline-sensitive gamma-amino-butyric acid (GABA) receptor binding.
    Mann E; Enna SJ
    Brain Res; 1980 Feb; 184(2):367-73. PubMed ID: 7353162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-HT1B receptor binding in degenerative movement disorders.
    Castro ME; Pascual J; Romón T; Berciano J; Figols J; Pazos A
    Brain Res; 1998 Apr; 790(1-2):323-8. PubMed ID: 9593971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study.
    Waeber C; Palacios JM
    Neuroscience; 1989; 32(2):337-47. PubMed ID: 2531301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease.
    Nishino N; Noguchi-Kuno SA; Sugiyama T; Tanaka C
    Brain Res; 1986 Jul; 377(1):186-9. PubMed ID: 2942224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain amino compounds in a Huntington's disease patient on isoniazid therapy.
    Perry TL; Wall RA; Hansen S
    Neurology; 1985 May; 35(5):755-8. PubMed ID: 3157886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased receptor-binding sites for kainic acid in brains of patients with Huntington's disease.
    London ED; Yamamura HI; Bird ED; Coyle JT
    Biol Psychiatry; 1981 Feb; 16(2):155-62. PubMed ID: 6452910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regional differences in the enhancement by GABA of [3H]zolpidem binding to omega 1 sites in rat brain membranes and sections.
    Ruano D; Benavides J; Machado A; Vitorica J
    Brain Res; 1993 Jan; 600(1):134-40. PubMed ID: 8380746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Striatal dopamine and homovanillic acid in Huntington's disease.
    Reynolds GP; Garrett NJ
    J Neural Transm; 1986; 65(2):151-5. PubMed ID: 2939198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GABA content and glutamic acid decarboxylase activity in brain of Huntington's chorea patients and control subjects.
    Urquhart N; Perry TL; Hansen S; Kennedy J
    J Neurochem; 1975 May; 24(5):1071-5. PubMed ID: 124764
    [No Abstract]   [Full Text] [Related]  

  • 39. Characterization of the gamma-aminobutyric acid receptor system in human brain gliomas.
    Frattola L; Ferrarese C; Canal N; Gaini SM; Galluso R; Piolti R; Trabucchi M
    Cancer Res; 1985 Sep; 45(9):4495-8. PubMed ID: 2992781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. gamma-Aminobutyric acid (GABA) receptor stimulation. II. Specificity of progabide (SL 76002) and SL 75102 for the GABA receptor.
    Lloyd KG; Arbilla S; Beaumont K; Briley M; De Montis G; Scatton B; Langer SZ; Bartholini G
    J Pharmacol Exp Ther; 1982 Mar; 220(3):672-7. PubMed ID: 6121050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.